PrEPaRe (PrEP and Resistance) is a new study within the RESPOND
network. The study is a pilot project designed to investigate PrEP use in people newly diagnosed with HIV. We aim at collecting information on people newly diagnosed with HIV who have taken PrEP prior to being diagnosed with HIV.
The study started in 2020 and enrolment will continue until 2022. PrEPaRe aims to enrol 160 patients during a three-year study period. It is taking place in 20 countries and currently, 72 sites have shown interest in participating.
Partners in the following countries have received the Ethics Committee approval: Poland, Denmark, Austria, Bosnia and Herzegovina, Czechia, two sites in Spain and one in Germany. The remaining countries estimate receiving EC approval by spring 2020.
We estimate to get all EC approval from the remaining counties in by Spring 2020.
For more information about the PrEPaRe Study, please contact the study coordinator Tina Bruun at email@example.com.